This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SoRelle, R. Search for Related Content PubMed PubMed Citation Articles by SoRelle, R.

(Circulation. 2004;109:e9028-e9030.)
© 2004 American Heart Association, Inc.

Cardiovascular News

Ruth SoRelle, MPH

Circulation Newswriter

An extract of the first 250 words of the full text is provided, because this article has no abstract.

From This Week’s Issue of Circulation: Stenosis and the Drug-Eluting Stent

Stenosis, identified through coronary angiography, occurs rarely after implantation of a sirolimus-eluting stent. However, when it does, it most often occurs because of factors relating to the lesion itself or in patients with diabetes, said researcher from The Netherlands in a report in this week’s issue of the journal Circulation ( Circulation. 2004;109:1366–1370[Abstract/Free Full Text]).

Researchers participating in the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) study evaluated a cohort of patients with complex disease who had been treated with sirolimus-eluting stent(s). A total of 238 patients with 441 lesions were identified and underwent angiographic follow-up 6 months after receiving their stents.

The researchers wrote, "Angiographic restenosis after SES [sirolimus-eluting stent] implantation in complex patients is an infrequent event (7.9% of lesions), occurring mainly in association with local, lesion-based characteristics and diabetes mellitus."

From the American College of Cardiology’s Scientific Sessions 2004
The Value of ACE Inhibitors in Diabetics PERSUADEd
NEW ORLEANS, La—Diabetics with stable coronary artery disease benefited as much from treatment with the ACE inhibitor perindopril as did their nondiabetic counterparts, said Kim Fox, MD, of The Brompton Hospital in London, during a late-breaking trials session of the American College of Cardiology Scientific Sessions 2004 meeting here March 6–10, 2004.

Kim Fox, MD

The diabetics were part of a study called PERSUADE (PERindopril SUbstudy in coronary Artery disease and DiabEtics), a substudy of EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease). The 1502 diabetic patients with stable coronary artery disease were randomly selected to receive 8 mg of perindopril daily or placebo. They were all receiving . . . [Full Text of this Article]